脓毒性休克期间氢化可的松持续输注与间断推注的比较:一项随机对照临床试验
该随机对照开放标签试验在大学医院内科ICU比较脓毒性休克患者氢化可的松间断推注与持续输注。纳入需去甲肾上腺素>2 mg/h(约33.3 μg/mn)且已充分液体复苏的成人患者,排除已用皮质激素、有禁忌、24小时内死亡及决定不复苏者。氢化可的松200 mg/d持续输注或50 mg每6小时推注,贯穿升压药使用期间,最长7天,每组29例。推注组休克逆转率显著更高(66% vs 35%,P=0.008),休克逆转中位时间推注组5天(95%CI 4.31-5.69)vs 持续输注组6天(95%CI 4.80-7.19),log Rank=0.048;血糖≥180 mg/dL小时数持续输注组中位64 h[IQR(2-100)] vs 推注组48 h[IQR(14-107)](P=0.60),每日胰岛素需求两组相似(P=0.63),其他副作用、死亡率和ICU住院时间两组相似。
要点
- 脓毒性休克需去甲肾上腺素>2 mg/h(约33.3 μg/mn)且已充分液体复苏的成人患者,氢化可的松50 mg每6小时推注组第7天休克逆转率66% vs 持续输注200 mg/d组35%(P=0.008)。
- 休克逆转中位时间推注组5天(95%CI 4.31-5.69)vs 持续输注组6天(95%CI 4.80-7.19),log Rank=0.048。
- 血糖≥180 mg/dL小时数持续输注组中位64 h[IQR(2-100)] vs 推注组48 h[IQR(14-107)](P=0.60),每日胰岛素需求两组相似(P=0.63)。
- 其他副作用、死亡率和ICU住院时间两组相似。
- 氢化可的松贯穿升压药使用期间给药,最长7天,推注方案为50 mg每6小时,持续输注方案为200 mg/d。
适用人群与场景
- 大学医院内科ICU的成人脓毒性休克患者,需去甲肾上腺素>2 mg/h(约33.3 μg/mn)且已充分液体复苏后纳入。
- 排除已接受皮质激素、有皮质激素禁忌、24小时内死亡及决定不复苏的患者。
处置流程与药物剂量
- 氢化可的松200 mg/d持续输注,或50 mg每6小时推注,贯穿升压药使用期间,最长7天。
研究设计与关键结果
- 随机对照开放标签试验,每组29例;推注组休克逆转率66% vs 持续输注组35%(P=0.008)。
- 休克逆转中位时间推注组5天(95%CI 4.31-5.69)vs 持续输注组6天(95%CI 4.80-7.19),log Rank=0.048。
- 血糖≥180 mg/dL小时数持续输注组中位64 h[IQR(2-100)] vs 推注组48 h[IQR(14-107)](P=0.60),每日胰岛素需求两组相似(P=0.63)。
- 其他副作用、死亡率和ICU住院时间两组相似。
证据类型、等级与局限
- 证据类型:随机对照开放标签试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,与持续输注相比,氢化可的松间断推注与第7天更高的休克逆转率相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: The best modality of administration of hydrocortisone during septic shock has been poorly evaluated and the guidelines remain unclear in this respect. This study aimed to compare bolus of hydrocortisone to a continuous infusion during septic shock.
DESIGN: Randomized controlled, open-label trial.
SETTING: Medical ICU of a university hospital.
PATIENTS: Adult patients with septic shock requiring more than 2 mg/h (approximately 33.3 μg/mn) of norepinephrine after adequate fluid administration were eligible.Patients already receiving corticosteroids or who have a contraindication to corticosteroids, patients who died within 24 h and those with a decision of not to resuscitate were excluded.
INTERVENTIONS: Patients were randomized either to receive hydrocortisone 200 mg/d by continuous infusion or by boluses of 50 mg every 6 h throughout the prescription of vasopressors with a maximum of 7 days.
RESULTS: Twenty-nine patients were included in each group. Shock reversal was significantly higher in the HC bolus group (66% vs. 35%, P = 0.008). The median time to shock reversal was 5 days (95% CI, 4.31-5.69) in the HC bolus group compared to 6 days (95% CI, 4.80-7.19) in the HC continuous infusion group (log Rank = 0.048). The number of hours spent with blood glucose ≥ 180 mg/dL was higher in the HC continuous infusion group with a median of 64 h [IQR (2-100)] versus 48 h [IQR (14-107)] in the HC bolus group, (P = 0.60), and daily insulin requirements were similar between the two groups (P = 0.63). The occurrence of other side effects, mortality, and ICU LOS were similar between the study groups.
CONCLUSION: Hydrocortisone administered by intermittent bolus was associated with higher shock reversal at day 7 compared with a continuous infusion.
参考来源
- Tilouche N, Jaoued O, Ali HBS, et al. Comparison Between Continuous and Intermittent Administration of Hydrocortisone During Septic Shock: A Randomized Controlled Clinical Trial. Shock. 2019. PMID: 30628950. doi:10.1097/SHK.0000000000001316
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。